Drug-Diagnostic Co-Development in Cancer-Reference-Cited by-同舟云学术

Drug-Diagnostic Co-Development in Cancer

Published:2010-12 Issue:6 Volume:24 Page:363-375
ISSN:1178-2595
Container-title:Pharmaceutical Medicine
language:en
Short-container-title:Pharm Med

Author:

Winther Henrik,Jørgensen Jan Trøst

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/BF03256837.pdf

Reference50 articles.

1. Jørgensen JT. From blockbuster medicine to personalized medicine. Per Med 2008; 5: 55–63

2. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 201–4

3. Roche Corporate Communication. Prospects: more knowledge for medical science. Genes and health. 3rd ed. Basel: F Hoffmann-La Roche Ltd, 2007: 127–36

4. Sikora K. Personalized cancer therapy: key to the future. Pharmacogenomics 2004; 5: 225–8

5. Jørgensen JT, Winther H. The new era of personalized medicine: 10 years later. Per Med 2009; 6: 423–8

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonparametric Finite Mixture: Applications in Overcoming Misclassification Bias;Journal of the American Statistical Association;2023-09-11

2. A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer;Frontiers in Oncology;2021-07-23

3. Companion Diagnostics: From Biomarkers to Diagnostics;Comprehensive Medicinal Chemistry III;2017

4. A new look at the corporate capability of personalized medicine development in the pharmaceutical industry;R&D Management;2014-05-28

5. Aplicación de la farmacogenómica y otras nuevas tecnologías al desarrollo de medicamentos;Medicina Clínica;2013-06